Pay in 4 interest-free payments of $5.73 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
WHO to endorse GLP-1 drugs for obesity, calls for global access The World Health Organization is poised to officially endorse GLP-1 medications like Wegovy and Zepbound for treating obesity in adults worldwide by August or September 2025
Researchers have studied an oral version of semaglutide along with another GLP-1 drug, orforglipron (brand name Foundayo), for weight loss
Aim for consistent fluid intake throughout the day
These included CT-996, a once-daily oral small-molecule oral GLP-1 receptor agonist, in Phase I, for treating obesity in patients with and without Type 2 diabetes, as well as two injectable clinical drug candidates: CT-388, a once-weekly subcutaneous injectable in Phase II, for treating obesity in patients with and without Type 2 diabetes, and CT-868, a once-daily subcutaneous injectable, in Phase II, for treating Type 1 diabetes patients with overweight or obesity
US$ 22.62
US$ 21.22
US$ 24.16
US$ 21.84
US$ 25.65
US$ 25.59
US$ 26.78
